PortfoliosLab logoPortfoliosLab logo
MLTX vs. OPAD
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

MLTX vs. OPAD - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in MoonLake Immunotherapeutics (MLTX) and Offerpad Solutions Inc. (OPAD). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, MLTX achieves a 41.81% return, which is significantly higher than OPAD's -59.09% return.


MLTX

1D
5.30%
1M
1.52%
YTD
41.81%
6M
26.37%
1Y
-57.54%
3Y*
-10.04%
5Y*
13.19%
10Y*

OPAD

1D
-2.37%
1M
-19.97%
YTD
-59.09%
6M
-71.88%
1Y
-51.47%
3Y*
-61.04%
5Y*
-68.09%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

MLTX vs. OPAD - Yearly Performance Comparison


2026 (YTD)202520242023202220212020
MLTX
MoonLake Immunotherapeutics
41.81%-75.66%-10.33%475.14%6.17%-13.02%6.26%
OPAD
Offerpad Solutions Inc.
-59.09%-57.54%-72.20%48.39%-92.80%-41.82%0.24%

Correlation

The correlation between MLTX and OPAD is 0.22, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.22

Correlation (3Y)
Calculated over the trailing 3-year period

0.21

Correlation (5Y)
Calculated over the trailing 5-year period

0.17

Correlation (All Time)
Calculated using the full available price history since Dec 11, 2020

0.17

Fundamentals

Market Cap

MLTX:

$1.33B

OPAD:

$228.66M

EPS

MLTX:

-$3.90

OPAD:

-$1.16

PB Ratio

MLTX:

5.24

OPAD:

4.99

Total Revenue (TTM)

MLTX:

$0.00

OPAD:

$487.19M

Gross Profit (TTM)

MLTX:

-$1.49M

OPAD:

$37.09M

EBITDA (TTM)

MLTX:

-$179.84M

OPAD:

-$29.30M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

MLTX vs. OPAD — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

MLTX
MLTX Risk / Return Rank: 3737
Overall Rank
MLTX Sharpe Ratio Rank: 2121
Sharpe Ratio Rank
MLTX Sortino Ratio Rank: 5252
Sortino Ratio Rank
MLTX Omega Ratio Rank: 6868
Omega Ratio Rank
MLTX Calmar Ratio Rank: 1919
Calmar Ratio Rank
MLTX Martin Ratio Rank: 2424
Martin Ratio Rank

OPAD
OPAD Risk / Return Rank: 3939
Overall Rank
OPAD Sharpe Ratio Rank: 3232
Sharpe Ratio Rank
OPAD Sortino Ratio Rank: 5757
Sortino Ratio Rank
OPAD Omega Ratio Rank: 5353
Omega Ratio Rank
OPAD Calmar Ratio Rank: 2222
Calmar Ratio Rank
OPAD Martin Ratio Rank: 2929
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

MLTX vs. OPAD - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for MoonLake Immunotherapeutics (MLTX) and Offerpad Solutions Inc. (OPAD). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


MLTXOPADDifference
Sharpe ratioReturn per unit of total volatility

-0.25

Sortino ratioReturn per unit of downside risk

-0.22

Omega ratioGain probability vs. loss probability

1.20

1.11

+0.09

Calmar ratioReturn relative to maximum drawdown

-0.64

-0.56

-0.08

Martin ratioReturn relative to average drawdown

-0.90

-0.75

-0.16

MLTX vs. OPAD - Sharpe Ratio Comparison

The current MLTX Sharpe Ratio is -0.50, which is lower than the OPAD Sharpe Ratio of -0.25. The chart below compares the historical Sharpe Ratios of MLTX and OPAD, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

MLTX vs. OPAD - Drawdown Comparison

The maximum MLTX drawdown since its inception was -90.22%, smaller than the maximum OPAD drawdown of -99.84%. Use the drawdown chart below to compare losses from any high point for MLTX and OPAD.


Loading charts...

Drawdown Indicators


MLTXOPADDifference

Max Drawdown

Largest peak-to-trough decline

-90.22%

-99.84%

+9.62%

Max Drawdown (1Y)

Largest decline over 1 year

-89.93%

-92.25%

+2.32%

Max Drawdown (3Y)

Largest decline over 3 years

-90.22%

-96.73%

+6.51%

Max Drawdown (5Y)

Largest decline over 5 years

-90.22%

-99.84%

+9.62%

Current Drawdown

Current decline from peak

-70.73%

-99.83%

+29.10%

Average Drawdown

Average peak-to-trough decline

-29.34%

-82.10%

+52.76%

Ulcer Index

Depth and duration of drawdowns from previous peaks

63.83%

68.98%

-5.15%

Volatility

MLTX vs. OPAD - Volatility Comparison

The current volatility for MoonLake Immunotherapeutics (MLTX) is 16.28%, while Offerpad Solutions Inc. (OPAD) has a volatility of 31.15%. This indicates that MLTX experiences smaller price fluctuations and is considered to be less risky than OPAD based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


MLTXOPADDifference

Volatility (1M)

Calculated over the trailing 1-month period

16.28%

31.15%

-14.87%

Volatility (6M)

Calculated over the trailing 6-month period

55.39%

75.12%

-19.73%

Volatility (1Y)

Calculated over the trailing 1-year period

115.66%

210.43%

-94.77%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

91.15%

131.30%

-40.15%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

86.34%

125.39%

-39.05%

Dividends

MLTX vs. OPAD - Dividend Comparison

Neither MLTX nor OPAD has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

MLTX vs. OPAD - Financials Comparison

This section allows you to compare key financial metrics between MoonLake Immunotherapeutics and Offerpad Solutions Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00200.00M400.00M600.00M800.00M1.00B1.20B1.40B202220232024202520260
80.08M
(MLTX) Total Revenue
(OPAD) Total Revenue
Values in USD except per share items

Frequently Asked Questions


MLTX and OPAD have a correlation of 0.22, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

OPAD has higher volatility (31.15%) compared to MLTX (16.28%). In terms of maximum drawdown, MLTX dropped -90.22% vs OPAD's -99.84%.

OPAD currently has the higher Sharpe Ratio (-0.25 vs -0.50), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for MLTX and OPAD

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer